Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT
Hudson Alakonya,Sofia Koustoulidou,Samantha L. Hopkins,Mathew Veal,Javier Ajenjo,Deborah Sneddon,Gemma Dias,Michael Mosley,Julia Baguña Torres,Francesca Amoroso,Amanda Anderson,Alison H. Banham,Bart Cornelissen
DOI: https://doi.org/10.2967/jnumed.124.267736
2024-10-02
Journal of Nuclear Medicine
Abstract:Mutations of p53 protein occur in over half of all cancers, with profound effects on tumor biology. We present the first—to our knowledge—method for noninvasive visualization of p53 in tumor tissue in vivo, using SPECT, in 3 different models of cancer. Methods: Anti-p53 monoclonal antibodies were conjugated to the cell-penetrating transactivator of transcription (TAT) peptide and a metal ion chelator and then radiolabeled with 111 In to allow SPECT imaging. 111 In-anti-p53-TAT conjugates were retained longer in cells overexpressing p53-specific than non–p53-specific 111 In-mIgG (mouse IgG from murine plasma)-TAT controls, but not in null p53 cells. Results: In vivo SPECT imaging showed enhanced uptake of 111 In-anti-p53-TAT, versus 111 In-mIgG-TAT, in high-expression p53 R175H and medium-expression wild-type p53 but not in null p53 tumor xenografts. The results were confirmed in mice bearing genetically engineered KPC mouse–derived pancreatic ductal adenocarcinoma tumors. Imaging with 111 In-anti-p53-TAT was possible in KPC mice bearing spontaneous p53 R172H pancreatic ductal adenocarcinoma tumors. Conclusion: We demonstrate the feasibility of noninvasive in vivo molecular imaging of p53 in tumor tissue using a radiolabeled TAT-modified monoclonal antibody.
radiology, nuclear medicine & medical imaging